ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ghosal, S
Right arrow Articles by Evans, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghosal, S
Right arrow Articles by Evans, M.
Eur Respir J 2000; 15: 146-150
Copyright © ERS Journals Ltd 2000

Original Articles

Sodium channel blockers and uridine triphosphate: effects on nasal potential difference in cystic fibrosis mice

S Ghosal, CJ Taylor, WH Colledge, R Ratcliff, and MJ Evans

Sodium channel inhibitors block the enhanced Na+ reabsorption in cystic fibrosis (CF). Extracellular nucleotides facilitate Cl- secretion via Ca2+ gated Cl- channels. A combination of these effects may produce less viscid secretions in CF which are easier to expectorate. This study examined the effects of combining sodium channel blockers with uridine triphosphate (UTP) on nasal membrane potential difference (PD) in CF insertional null mutant mice (cftr(tm1HGU)), deltaF508 homozygous mice (cftr(tm1Cam)) and matched control animals. Median basal PD in the insertional CF mice and deltaF508 CF mice were -28 and -34 mV respectively. These values were significantly different to the control animals (-20 mV). Amiloride and loperamide reduced the PD in cftr(tm1HGU) CF mice (deltaPD 13 mV & 15 mV respectively) suggesting Na+ blockade. The subsequent addition of UTP in a chloride-free vehicle increased the PD (deltaPD -8- -12.5 mV). DeltaF508 mice showed significantly greater responses compared with CF insertional null mutant mice (p<0.05). The action of UTP was brief and not prolonged by the addition alpha-beta-methylene-adenosine 5' diphosphate. Suramin, a competitive antagonist of P2 purinoceptors blocked the action of UTP. In conclusion, this study demonstrated dose dependant nasal membrane potential changes in differences mice with uridine triphosphate in the presence of sodium channel blockers suggestive of chloride secretion. More stable analogues of uridine triphosphate in combination with long acting sodium channel blockers such as loperamide may have therapeutic potential in cystic fibrosis.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
B. Lubamba, H. Lecourt, J. Lebacq, P. Lebecque, H. De Jonge, P. Wallemacq, and T. Leal
Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 506 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. B. Salinas, N. Pedemonte, C. Muanprasat, W. F. Finkbeiner, D. W. Nielson, and A. S. Verkman
CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor
Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L936 - L943.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. G. Brady, T. J. Kelley, and M. L. Drumm
Examining basal chloride transport using the nasal potential difference response in a murine model
Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1173 - L1179.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H.C. Rodgers and A.J. Knox
Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Eur. Respir. J., June 1, 2001; 17(6): 1314 - 1321.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.